From the analysis of the VAERS system, they identified the incidence of myopericarditis after BNT162b2 vaccination in adolescents aged 12 to 17 years. They reported 253 cases of myopericarditis, the incidence per million after the second dose in male patients 162.2 and 93.0, respectively. Cases occurred at a median of 2.0 days after vaccination. The hospitalization rate was 220/253 (86.9%). These findings support individualized pediatric COVID-19 vaccination strategies that weigh protection against severe disease against the risks of vaccine-associated myopericarditis.